THE 10th SUGIYAMA LABORATORY (RIKEN) OPEN SYMPOSIUM
“Role of DMPK scientists in bringing precision medicine into real-world”

Date: 13:50 - 17:50, October 20th, 2017
Venue: RIKEN Yokohama Main Office Building Hall

13:50-14:00 Opening remarks
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN Innovation Center)

Chair: Yuichi Sugiyama (Sugiyama Laboratory, RIKEN Innovation Center)
14:00-14:30 Systems-based understandings of drug toxicities
Masashi Honma (The University of Tokyo Hospital)

Chair: Yuichi Sugiyama (Sugiyama Laboratory, RIKEN Innovation Center)
14:30-15:00 Current Approaches for Evaluating OATP Family Transporters in Drug Discovery
Saki Izumi (Eisai Co., Ltd.)

Chair: Shinji Yamazaki (Pfizer Inc.)
15:00-15:30 Complex DDI of telaprevir and maraviroc
Emi Kimoto (Pfizer Inc.)

15:30-15:50 Coffee break

Chair: Shinji Yamazaki (Pfizer Inc.)
15:50-16:20 Physiologically based pharmacokinetic (PBPK) modeling approach of cerivastatin to quantitatively describe drug-drug interactions associated with hepatic uptake transporter and metabolic enzymes
Yoshiaki Yao (Astellas Pharma Inc.)

Chair: Kazuya Maeda (The University of Tokyo)
16:20-16:50 Kinetic consideration of OATP contribution to drug disposition based on extended clearance concept: Insight to genetic and ethnic variability and drug-drug interaction
Yoshiko Tomita (Sumitomo Dainippon Pharma Co., Ltd.)

Chair: Kazuya Maeda (The University of Tokyo)
16:50-17:20 Bilirubin and its conjugates levels in the blood circulation can be a bio-marker for drug-drug interaction?: Various drug transporters/drug-metabolism enzymes are involved in bilirubin homeostasis
Seiji Miyauchi (Toho university)

17:20-17:50 General Discussion
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN Innovation Center)

18:00-19:45 Banquet (Cafeteria at Yokohama RIKEN)

[This Symposium is a part of the RIKEN Symposium Series.]